Drug Discovery Market Size, Share, Trends, Growth Outlook

Drug Discovery Market is estimated to increase at a Compounded Annual Growth Rate of 9.8% CAGR over the forecast period from 2024 to 2030

The Drug Discovery Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Drug (Small Molecule Drugs, Biologic Drugs), By Technology (High Throughput Screening, Pharmacogenomics, Combinatorial Chemistry, Nanotechnology, Others), By End-User (Pharmaceutical Companies, Contract Research Organizations (CROs), Others).

An Introduction to Drug Discovery Market in 2024

In 2024, the market for drug discovery addresses the complex and multifaceted process of identifying, designing, and developing novel therapeutic compounds for the treatment of human diseases, offering a wide array of technologies, platforms, and services to support drug discovery research and development efforts in pharmaceutical companies, biotechnology firms, academic institutions, and contract research organizations (CROs). Drug discovery involves target identification, lead generation, lead optimization, preclinical testing, and candidate selection phases, leveraging interdisciplinary approaches such as medicinal chemistry, molecular biology, pharmacology, and computational modeling to identify promising drug candidates with desired pharmacological profiles and therapeutic potential. Key technologies and methodologies employed in drug discovery include high-throughput screening (HTS), virtual screening, structure-based drug design, fragment-based drug discovery, phenotypic screening, and artificial intelligence (AI)-driven approaches, enabling rapid and efficient exploration of chemical space, target validation, and hit-to-lead optimization. With a focus on innovation, collaboration, and translational research, the drug discovery market fosters partnerships, consortia, and open-access initiatives to accelerate the discovery and development of new drugs, address unmet medical needs, and advance therapeutic interventions across a wide range of therapeutic areas and disease conditions. Moreover, with advancements in genomics, proteomics, and precision medicine approaches, the drug discovery market continues to evolve, offering novel insights into disease biology, personalized treatment strategies, and targeted therapies for improving patient outcomes and reshaping the landscape of modern medicine.

Market Trend: Integration of Artificial Intelligence and Machine Learning in Drug Discovery

A prominent trend in the drug discovery market is the increasing integration of artificial intelligence (AI) and machine learning (ML) technologies. These advanced computational tools are revolutionizing the drug discovery process by enabling researchers to analyze vast amounts of biological, chemical, and clinical data to identify potential drug targets, predict drug candidates, and optimize drug development strategies. AI and ML algorithms offer capabilities such as predictive modeling, virtual screening, and molecular simulation, which accelerate the identification and optimization of novel drug candidates while reducing the time and costs associated with traditional drug discovery approaches. This trend is driven by the need for more efficient and cost-effective drug development solutions, as well as the growing availability of big data and computing resources to support AI-driven drug discovery initiatives. As AI and ML technologies continue to evolve, their integration into drug discovery workflows holds the potential to revolutionize the pharmaceutical industry and improve the success rate of drug development programs.

Market Driver: Increasing Demand for Novel Therapeutics and Personalized Medicine

A key driver for the drug discovery market is the increasing demand for novel therapeutics and personalized medicine approaches. With the growing prevalence of complex diseases such as cancer, neurological disorders, and rare genetic conditions, there is a critical need for innovative treatments that address unmet medical needs and improve patient outcomes. Additionally, the shift towards personalized medicine, which involves tailoring treatment strategies to individual patient characteristics and genetic profiles, drives the demand for targeted therapies and precision medicine solutions. Drug discovery plays a pivotal role in meeting these demands by identifying new drug targets, developing targeted therapies, and advancing personalized treatment approaches. The urgent need for innovative drugs and personalized treatment options motivates pharmaceutical companies, research institutions, and biotechnology firms to invest in drug discovery research and development, propelling market growth in the drug discovery segment.

Market Opportunity: Exploration of Novel Drug Modalities and Therapeutic Areas

An opportunity for innovation and market expansion in the drug discovery market lies in the exploration of novel drug modalities and therapeutic areas. Traditional small-molecule drugs and biologics have been the mainstays of drug discovery for decades, but emerging technologies and scientific advancements offer opportunities to explore new drug modalities such as gene therapy, cell therapy, RNA-based therapeutics, and nanomedicine. Additionally, there is potential to target previously unexplored therapeutic areas such as rare diseases, infectious diseases, and age-related conditions, where significant medical needs exist and traditional drug discovery approaches may have limitations. By investing in research and development of novel drug modalities and therapeutic areas, companies can diversify their drug pipelines, address unmet medical needs, and capitalize on emerging market opportunities in the dynamic landscape of drug discovery.

Drug Discovery Market Share Analysis: Biologic Drugs

The Biologic Drugs segment within the Drug Discovery market is experiencing rapid growth due to several factors driving the demand for innovative biopharmaceuticals in drug development pipelines. Biologic drugs, also known as biologics, are therapeutic agents derived from living organisms, including proteins, antibodies, peptides, and nucleic acids. These drugs offer unique mechanisms of action and therapeutic benefits, making them valuable treatments for a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. With advancements in biotechnology and genetic engineering, biologic drugs have revolutionized the treatment landscape, providing targeted and personalized therapies with fewer side effects compared to traditional small molecule drugs. Additionally, the increasing understanding of disease pathways and the human genome has led to the identification of novel drug targets and biomarkers, driving the demand for innovative biologic therapies. Pharmaceutical companies and contract research organizations (CROs) are investing heavily in biologics research and development, fueling the growth of the Biologic Drugs segment in the Drug Discovery market. Moreover, the expansion of biologics manufacturing capabilities and the regulatory support for biopharmaceutical development further contribute to the segment's rapid expansion. With ongoing advancements in biologics technology and the increasing focus on precision medicine approaches, the Biologic Drugs segment is poised to continue its rapid growth trajectory, shaping the future of drug discovery and personalized healthcare.

Drug Discovery Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbVie Inc, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co. Inc, Novartis AG, Pfizer Inc, Sanofi SA, Takeda Pharmaceutical Company Ltd

Drug Discovery Market Segmentation

By Drug
Small Molecule Drugs
Biologic Drugs
By Technology
High Throughput Screening
Pharmacogenomics
Combinatorial Chemistry
Nanotechnology
Others
By End-User
Pharmaceutical Companies
Contract Research Organizations (CROs)
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Drug Discovery Market Companies

AbbVie Inc
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Merck & Co. Inc
Novartis AG
Pfizer Inc
Sanofi SA
Takeda Pharmaceutical Company Ltd

Reasons to Buy the Drug Discovery Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Drug Discovery Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Drug Discovery Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Drug Discovery Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Drug Discovery Market Size Outlook, $ Million, 2021 to 2030
3.2 Drug Discovery Market Outlook by Type, $ Million, 2021 to 2030
3.3 Drug Discovery Market Outlook by Product, $ Million, 2021 to 2030
3.4 Drug Discovery Market Outlook by Application, $ Million, 2021 to 2030
3.5 Drug Discovery Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Drug Discovery Industry
4.2 Key Market Trends in Drug Discovery Industry
4.3 Potential Opportunities in Drug Discovery Industry
4.4 Key Challenges in Drug Discovery Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Drug Discovery Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Drug Discovery Market Outlook by Segments
7.1 Drug Discovery Market Outlook by Segments, $ Million, 2021- 2030
By Drug
Small Molecule Drugs
Biologic Drugs
By Technology
High Throughput Screening
Pharmacogenomics
Combinatorial Chemistry
Nanotechnology
Others
By End-User
Pharmaceutical Companies
Contract Research Organizations (CROs)
Others

8 North America Drug Discovery Market Analysis and Outlook To 2030
8.1 Introduction to North America Drug Discovery Markets in 2024
8.2 North America Drug Discovery Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Drug Discovery Market size Outlook by Segments, 2021-2030
By Drug
Small Molecule Drugs
Biologic Drugs
By Technology
High Throughput Screening
Pharmacogenomics
Combinatorial Chemistry
Nanotechnology
Others
By End-User
Pharmaceutical Companies
Contract Research Organizations (CROs)
Others

9 Europe Drug Discovery Market Analysis and Outlook To 2030
9.1 Introduction to Europe Drug Discovery Markets in 2024
9.2 Europe Drug Discovery Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Drug Discovery Market Size Outlook by Segments, 2021-2030
By Drug
Small Molecule Drugs
Biologic Drugs
By Technology
High Throughput Screening
Pharmacogenomics
Combinatorial Chemistry
Nanotechnology
Others
By End-User
Pharmaceutical Companies
Contract Research Organizations (CROs)
Others

10 Asia Pacific Drug Discovery Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Drug Discovery Markets in 2024
10.2 Asia Pacific Drug Discovery Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Drug Discovery Market size Outlook by Segments, 2021-2030
By Drug
Small Molecule Drugs
Biologic Drugs
By Technology
High Throughput Screening
Pharmacogenomics
Combinatorial Chemistry
Nanotechnology
Others
By End-User
Pharmaceutical Companies
Contract Research Organizations (CROs)
Others

11 South America Drug Discovery Market Analysis and Outlook To 2030
11.1 Introduction to South America Drug Discovery Markets in 2024
11.2 South America Drug Discovery Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Drug Discovery Market size Outlook by Segments, 2021-2030
By Drug
Small Molecule Drugs
Biologic Drugs
By Technology
High Throughput Screening
Pharmacogenomics
Combinatorial Chemistry
Nanotechnology
Others
By End-User
Pharmaceutical Companies
Contract Research Organizations (CROs)
Others
12 Middle East and Africa Drug Discovery Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Drug Discovery Markets in 2024
12.2 Middle East and Africa Drug Discovery Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Drug Discovery Market size Outlook by Segments, 2021-2030
By Drug
Small Molecule Drugs
Biologic Drugs
By Technology
High Throughput Screening
Pharmacogenomics
Combinatorial Chemistry
Nanotechnology
Others
By End-User
Pharmaceutical Companies
Contract Research Organizations (CROs)
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Merck & Co. Inc
Novartis AG
Pfizer Inc
Sanofi SA
Takeda Pharmaceutical Company Ltd

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Drug
Small Molecule Drugs
Biologic Drugs
By Technology
High Throughput Screening
Pharmacogenomics
Combinatorial Chemistry
Nanotechnology
Others
By End-User
Pharmaceutical Companies
Contract Research Organizations (CROs)
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)